Race, Ethnicity, and Diffuse Parenchymal Lung Disease
Overview
The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.
Full Title of Study: “Determinants of Outcome in Diffuse Parenchymal Lung Disease”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: August 2013
Detailed Description
It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities.
Participating in This Clinical Trial
Inclusion Criteria
- Diagnosis of IPF or other DPLD according to ATS criteria – Signed informed consent Exclusion Criteria:
- None
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Columbia University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Provider of Information About this Clinical Study
- Principal Investigator: David J. Lederer, M.D., Irving Assistant Professor of Medicine (in Pediatrics) – Columbia University
- Overall Official(s)
- David J Lederer, M.D., Principal Investigator, Columbia University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.